Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 10/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17682125 | 0.86 | EPHX2 (0.36) | EPHX2DPP4ALDH1A1SMN1; SMN2 | |
| SCHEMBL102472 | 0.77 | POLB (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL14661822 | 0.76 | OPRM1 (0.47) | EPHX2DPP4SMN1; SMN2 | |
| SCHEMBL2879833 | 0.74 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3523 | 0.74 | SMN1; SMN2 (0.37) | DPP4ALDH1A1SMN1; SMN2 | |
| SCHEMBL23219992 | 0.73 | ALDH1A1 (0.33) | ESR1ESR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL21607430 | 0.73 | ALDH1A1 (0.33) | ESR1ESR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL23220056 | 0.73 | ALDH1A1 (0.33) | ESR1ESR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2505 | 0.73 | SMN1; SMN2 (0.36) | DPP4ALDH1A1SMN1; SMN2 | |
| SCHEMBL14671094 | 0.73 | DPP4 (0.34) | EPHX2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226923-B2 | Spirocyclic molecules as protein kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-01-05 | — | — | US | disclosed |
| US-20140243303-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | BETA PHARMA CANADA INC. (CA) | 2014-08-28 | — | — | US | disclosed |
| WO-2013013308-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | BETA PHARMA CANADA INC. (CA) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243303-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | MET, RET, ALK | EPHX2 2203/4885DPP4 2832/4885AKT1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.